ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1923

Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?

Elena Nikiphorou1, Sam Norton2, Adam Young3, Lewis Carpenter2, Josh Dixey4, David Walsh5 and Patrick Kiely6, 1Academic Rheumatology, Department of Inflammation Biology, King's College London, London, Great Britain, 2Academic Rheumatology, King's College London, London, United Kingdom, 3University of Hertfordshire, Hertford, United Kingdom, 4Rheumatology, The Royal Wolverhampton, Wolverhampton, United Kingdom, 5Academic Rheumatology, University of Nottingham, Nottingham, Great Britain, 6Rheumatology Dept, St Georges Hospital, London, Great Britain

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity, Health Assessment Questionnaire, quality of life, rheumatoid arthritis (RA) and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: 4M104 ACR Abstract: Patient Outcomes, Preferences, & Attitudes I: Beliefs & Behaviors (1923–1928)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Treating Rheumatoid Arthritis To Target: Is Low Disease Activity Good Enough?

Background/Purpose:  It is now widely recognised that treat-to-target (T2T) principles in rheumatoid arthritis (RA) are effective in achieving optimal disease outcomes. The aim of this study was to examine for differences in outcomes between low (LDAS) and remission (RDAS) disease activity score (DAS) categories, to establish whether LDAS is an acceptable treatment target in RA.
Methods: Data from two consecutive, similarly designed UK multi-centre RA inception cohorts, were used: the Early RA Study (ERAS) and Early RA Network (ERAN). Recruitment figures/median follow up for ERAS and ERAN were 1465/10 years (maximum 25 years), and 1236/6 years (maximum 10 years) respectively. Standard demographic and clinical variables were recorded at baseline and then annually until the end of study follow up. Disease activity was categorised by mean DAS28 score between years 1-5 as remission [mRDAS<2.6] or low [mLDAS 2.6-3.2]; as sustained low/remission DAS (sLDAS/sRDAS) based on DAS persisting in each of the two categories at years 1-2 and as Boolean remission (years 1-2). Change in HAQ and SF36 (physical [PCS] and mental [MCS] components) for each disease activity category were modelled using linear mixed models with time incorporated as a linear spline with change-point at 12 months. Year of onset, age, gender and use of steroids or conventional DMARDS at first visit were included as covariates.
Results: Out of 2701 patients, 468 (17%) were in mRDAS, 284 (11%) in mLDAS in the first five years of disease. Lower proportions had achieved sRDAS (8%), sLDAS (6%) and Boolean (2%) remission (table). Mean age was similar across categories; more women were in low vs remission DAS. Compared to mLDAS or sLDAS, inflammatory markers, DAS, functional (HAQ, PCS) and mental (MCS) scores tended to be better in the mRDAs, sRDAS or Boolean remission categories. Significant differences (p<0.05) were noted between the mRDAS and mLDAS between years 1-5 for all outcomes; for sRDAS compared to sLDAS, the difference was significant at one year but not by five years (figure).

Conclusion: This study demonstrates striking differences between remission and low DAS categories, suggesting worse functional and SF36 outcomes over time in the low DAS categories. The findings support that remission should be the primary T2T goal in in RA.

Figure. Disease outcomes by DAS category.

 


Disclosure: E. Nikiphorou, None; S. Norton, None; A. Young, None; L. Carpenter, None; J. Dixey, None; D. Walsh, Pfizer, Inc., 5; P. Kiely, None.

To cite this abstract in AMA style:

Nikiphorou E, Norton S, Young A, Carpenter L, Dixey J, Walsh D, Kiely P. Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/treating-rheumatoid-arthritis-to-target-is-low-disease-activity-good-enough/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treating-rheumatoid-arthritis-to-target-is-low-disease-activity-good-enough/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology